Aug 21 (Reuters) - Syros Pharmaceuticals Inc
* Syros receives fda orphan drug designation for SY-1425 for treatment of AML
* Syros Pharmaceuticals Inc- look forward to presenting initial clinical data from ongoing Phase 2 clinical trial of SY-1425 in Q4 of this year Source text for Eikon: Further company coverage: